Mezavant XL launched for ulcerative colitis

Shire has launched Mezavant XL (mesalazine), indicated for the induction of clinical and endoscopic remission in patients with mild to moderate, active ulcerative colitis and for the maintenance of remission.

Mezavant is available as 1200mg gastro-resistant prolonged-release tablets. The recommended dose for induction of remission is two to four tablets taken once daily with food.

The highest dose of four tablets daily is recommended for patients not responding to lower doses of mesalazine. When using the highest dose, the effect of the treatment should be evaluated at eight weeks.

The recommended dose for maintenance of remission is two tablets taken once daily.

 

Further information: Shire 01256 894000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more